Clinical Trial

Disease: Primary Open Angle Glaucoma, POAG, (NCT06465537)

Disease info:

Open-angle glaucoma (OAG) is the most common type of Glaucoma. Glaucoma is a group of eye conditions that can damage the optic nerve which is responsible for transmitting images to the brain. Commonly such optic nerve damage is caused by increased pressure in the eye known as intraocular pressure. In OAG, the increase in pressure is often small and progresses slowly over time. The exact cause of the pressure increase in OAG remains unknown and usually cannot be felt by patients. The resulting damage to the optic nerve causes blind spots in the vision.

OAG tends to run in families, with an increased risk for individuals who have a parent or grandparent with the condition. Additionally, people of African descent are at a higher risk of developing the disease. Juvenile or early onset OAG is a rare type of primary open-angle glaucoma (POAG) that is caused by genetic variations. The MYOC gene, a gene heavily associated with early onset POAG encodes a protein called myocilin which is found in trabecular meshwork and the ciliary body, a structure in the eye that regulates the intraocular pressure.


Approximately 10-33% of individuals with early onset of POAG have variants in the MYOC gene. These variants can occur from genetic inheritance but also from external sources such as virus infection. MYOC gene variants have also been detected in some individuals with primary congenital glaucoma. 

Mutations in the TMCO1 gene also appear to be associated with POAG in certain populations but not in others. Specifically how these genetic variations affect OAG remains unknown.

Frequency:
Early onset OAG affects about 1 in 50,000 individuals worldwide. POAG is most commonly diagnosed after the age of 40, affecting about 1-2% of the population worldwide.
Official title:
A Clinical Study on CRISPR/Cas9 Instantaneous Gene Editing Therapy to Primary Open-angle Glaucoma With Elevated Intraocular Pressure and MYOC Gene Mutation
Who:

Contact

Name: Fujun Li, M.D.

Phone: 086-191 2131 1061

Email: fujun.li@bdgene.cn

Partners:

Beijing Tongren Hospital

Locations:

China, Beijing

Beijing Tongren Hospital, Capital Medical University, Beijing, Beijing, China, 100730

Study start:
Jun. 10, 2024
Enrollment:
9 particpants
Gene editing method:
CRISPR-Cas9
Type of edit:
Gene knockout
Gene:
MYOC gene
Delivery method:
Virus-like particle (VLP) - In-vivo
IND Enabling Pre-clinical
Phase I Safety
Phase II Safety and Dosing
Phase III Safety and Efficacy

Status: Active recruiting

Description

This study is intented to evaluate the safety, tolerability and preliminary efficacy of CRISPR/Cas9 Instantaneous Gene Editing Therapy (BD113 virus-like particle, also BD113vLVP) in patients with primary open-angle glaucoma (POAG) with elevated intraocular pressure and MYOC gene mutation. The main objectives to evaluate the safety and tolerability BD113vLVP) in POAG patients with intraocular hypertension and MYOC mutation, and secondary objectives is to explore the preliminary efficacy and the metabolism characteristics of BD113vLVP in participants.

This is an open, single-dose, two-arm, non-randomised clinical study. A total of 6 to 9 POAG patients with high intraocular pressure were enrolled and divided into two test groups. Test Group 1 recruits 3 POAG patients, who have elevated IOP and positive or negative MYOC mutation and target interventing eye is no vision. Test Group 2 will recruit 3 to 6 POAG patients with MYOC mutations and visual acuity. In order to better verify the lowering IOP effectiveness of BD113vVLP, another 2 or 3 participants will be recruied in Group 2 on-demand. Each participant will receive single dosing BD113vVLP (4µg p24) by intracameral injection in the interventing eye, then conduct the evaluations of the safety and efficacy according to visit schedule in 1 year follow-up.

Last updated: Oct. 9, 2024
close
Search CRISPR Medicine